Clinical Trial Update: Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy. [Phase 3]

View source ↗

Summary

Phase 3 trial update notes fluid retention in rosiglitazone-treated subjects with autonomic diabetic neuropathy. The communication highlights a safety signal re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neuropathy, Diabetic | Phase 3 | Status: COMPLETED